Date: 2015-05-27
Type of information: Development agreement
Compound: multiplex infectious disease tests to run on the Biocartis Idylla™ system
Company: Biocartis (Belgium) Fast-track diagnostics (Luxembourg)
Therapeutic area: Infectious diseases - Diagnostic
Type agreement: development collaboration
Action mechanism:
Disease: upper respiratory tract infections
Details: * On May 27, 2015, Biocartis, an innovative molecular diagnostics company and Fast-track diagnostics, a leading provider of multiplex polymerase chain reaction (PCR) test kits for infectious disease, announced that they have entered into a strategic collaboration to develop a range of multiplex infectious disease tests to run on the Biocartis Idylla™ system. Biocartis and Fast-track diagnostics plan to collaborate on a new approach to infectious disease diagnostics, “syndromic multiplex testing,” which enables the identification of a broader range of disease pathogens in a single test. Most current methods focus on the detection of one or a few pathogens expected to be present in a patient sample. If the sample is negative, a new test will be performed for other pathogens, increasing the time to result. With syndromic multiplex tests, the initial test will not just look for the most likely pathogen, but also for a range of less likely pathogens, preventing the need to retest. As part of the collaboration, tests from Fast-track diagnostics’ comprehensive infectious disease menu will be developed for use on Biocartis’ innovative molecular diagnostics (MDx) platform, Idylla™. Idylla™ is a fully-automated MDx system that delivers accurate, rapid tests in virtually any setting, from virtually any biological sample type, and without the need for pre-processing or specialist training. The first assay to be developed under the collaboration is a multiplex respiratory panel for the detection of viral and bacterial targets in upper respiratory tract infections.
Financial terms: Financial details of the agreement are not disclosed.
Latest news:
